Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

UConn taps into cell communication

A new technology discovered by a team including UConn School of Dental Medicine researchers records cellular communication in real time – providing a closer look...

| By Kelley Gipson

Intensity Therapeutics to collaborate with Merck

Intensity Therapeutics reports it has entered into an agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the...

| By Kelley Gipson

UConn alcohol research center continues run

Despite increasing competition for federal research dollars, the Alcohol Research Center at UConn Health endures well into its fifth decade with an unprecedented continuation of...

| By Kelley Gipson

CT creates new workforce training entity

Connecticut lawmakers have seeded a newly created workforce fund with $1 million, and created a new board within the state’s Department of Labor to make grants...

| By Kelley Gipson

UConn ranked top 10 for biological data research

According to CSRankings, an organization which compiles a metrics-based rankings of the top computer science programs in the world, the University of Connecticut ranks among...

| By Kelley Gipson

Cybrexa closes $13.4m B1 funding round

Cybrexa Therapeutics has completed a $13.4 million Series B1 financing. “This level of financial support from our investors demonstrates the continued enthusiasm and validation for...

| By Kelley Gipson

Shoreline Biome to Launch Product Suite

Shoreline Biome plans to unveil the market’s first end-to-end sample prep kit at the upcoming ASM Microbe 2019. The kit, Shoreline Complete, is an end-to-end...

| By Kelley Gipson

Yale studies biology of hunger hormone leptin

In a new study, Yale researchers offer insight into leptin, a hormone that plays a key role in appetite, overeating, and obesity. Their findings advance...

| By Kelley Gipson

FDA allows ReNetX Bio IND re spinal cord injury

ReNetX Bio reports that the FDA has has allowed the Company’s Investigational New Drug (IND) application for its lead drug candidate, fusion protein AXER-204. Axonal loss...

| By Kelley Gipson

FDA accepts Melinta application re BAXDELA®

Melinta Therapeutics reports that the FDA has accepted a supplemental New Drug Application for BAXDELA® (delafloxacin) for priority review. The application seeks to expand the current indication for...